Optimizing Outcomes for Patients With Relapsed Metastatic Cervical Cancer

Join us for a live CME/CE/CPE-certified Interdisciplinary Team Workshop Series to hear from experts on the latest data and therapeutic options for patients with cervical cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome, Introduction, Polling, and Presurvey Questions

Advances in Current Management of Cervical Cancers

  • Cervix cancer overview
    • HPV Infection and tumorigenesis
    • HPV vaccination and preventative measures
  • Current treatments algorithms for advanced/metastatic cervix cancer
  • Novel therapies in development
    • Immunotherapy
    • Antibody–drug conjugates
    • Case-based discussion of current data

Audience Q&A Session


Date / Time
Event Details


Program Director
Linda R. Duska, MD, MPH

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Program Director
Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this program is to improve patient care by increasing healthcare professional knowledge, competence, and performance in applying new data and managing adverse events of new therapies in the increasingly complex treatment landscape in advanced cervical cancer.

Target Audience
This program is intended for oncologists, oncology nurses, nurse practitioners, pharmacists, and other healthcare professionals involved in the care and management of patients with advanced cervical cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the mechanism of action of novel therapies used to treat recurrent/metastatic cervical cancer.
  • Plan therapy for patients with metastatic cervical cancer based on available data, expert recommendations, and consideration of optimal treatment sequencing
  • Collaborate with gynecologic oncology and multidisciplinary colleagues to prevent and―if necessary―manage treatment-related symptoms from recently approved targeted agents and ICI-based therapies


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-148-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.